Rolling update of the medium- to long-term growth strategy and disclosure of capital allocation policy. Strengthening business portfolios across eye care, skin care, oral supplements\/ingestion, food, and medical segments, targeting net sales of 415 billion yen and operating income of 54 billion yen by fiscal 2030. Maintains and aims to expand shareholder returns with a dividend payout ratio of 30% or more and indicates plans to increase the overseas sales ratio.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4527","jir_company_name":"Rohto Pharmaceutical Co.,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4527-20261002-02.pdf","jir_short_summary":"Rolling update of the medium- to long-term growth strategy and disclosure of capital allocation policy. Strengthening business portfolios across eye care, skin care, oral supplements\/ingestion, food, and medical segments, targeting net sales of 415 billion yen and operating income of 54 billion yen by fiscal 2030. Maintains and aims to expand shareholder returns with a dividend payout ratio of 30% or more and indicates plans to increase the overseas sales ratio.","jir_summary":"### Overview of Medium- to Long-Term Growth Strategy\nRohto Pharmaceutical Co.,Ltd. is performing a rolling update of its medium- to long-term growth strategy, focusing on growth of its core businesses\u2014eye care and skin care\u2014while expanding into new areas including oral supplements\/ingestion, food, and medical fields. The company will promote value creation by leveraging technological capabilities and intellectual property and accelerate global expansion. It presented fiscal 2024 actual results and targets for fiscal 2030, planning to raise the overseas sales ratio to around 53%.\n\n### Shareholder Returns and Capital Policy Direction\nAs a capital policy, the company clarified reallocating cash allocation to balance growth investments and shareholder returns. It will continue a dividend payout ratio of 30% or more and indicated the possibility of targeting around 40% by 2030. The company intends to build the next-generation high-profit base through increased DX\/IT investment and R&D expenditures.","jir_financial_highlights":"Net Sales: 3,086 hundred million yen (Fiscal 2024 actual, Fiscal 2030 forecast 4,150 hundred million yen)\nOperating Income: 382 hundred million yen (Fiscal 2030 forecast 540 hundred million yen)\nOperating Margin: 12.4% (Fiscal 2030 forecast 13.0%)","jir_category":"","jir_hashtags":"#RohtoPharmaceutical, #MediumToLongTermGrowthStrategy, #CapitalPolicy, #BusinessPortfolio, #ESGSustainability","jir_key_figures":"Net Sales: 3,086 hundred million yen (Fiscal 2024 actual) \u2192 Fiscal 2030 forecast 4,150 hundred million yen\nOperating Income: 382 hundred million yen (Fiscal 2024 actual) \u2192 Fiscal 2030 forecast 540 hundred million yen\nOverseas Sales Ratio: 47% (Fiscal 2024) \u2192 Fiscal 2030 forecast 53%","jir_meta_title":"Rohto Pharmaceutical Co.,Ltd. Rolling Update of Medium- to Long-Term Growth Strategy and Capital Allocation Policy | October 2026","jir_meta_description":"Rohto Pharmaceutical Co.,Ltd. announces a rolling update to its medium- to long-term growth strategy and capital policy. Focused on eye care and skin care, expanding into oral supplements, food, and medical fields, increasing overseas ratio, and setting future dividend payout ratio targets.","jir_og_title":"Rohto Pharmaceutical Co.,Ltd. Medium- to Long-Term Growth Strategy and Capital Policy","jir_og_description":"Explains the rolling update of the medium- to long-term growth strategy and capital allocation policy. Targets net sales of 415 billion yen and operating income of 54 billion yen, increases overseas ratio, and strengthens shareholder return policy.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":7770,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-127118","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n